We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Seegene

  Gold Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Unveils New STARlet-AIOS All-in-One Solution for All Molecular Testing at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
STARlet-AIOS All-in-One Solution
STARlet-AIOS All-in-One Solution

Seegene, Inc. (Seoul, Korea) unveiled its new STARlet-AIOS All-in-One Solution for All Molecular Testing at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30.

Over the span of the four day event, attendees connected with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine.

At AACC 2021, Seegene introduced its new STARlet-AIOS which is a unique modular configuration that integrates existing standalone instruments, enabling easy installation, upgrade and maintenance. Combined with Seegene's proprietary high-multiplex real-time PCR reagent technology, Seegene STARlet-AIOS provides an ultimate solution that could perform various syndromic tests with one system. The STARlet-AIOS is the world's one and only modular concept that enables a fully automated workflow while maintaining the standalone instruments, STARlet and CFX96 Dx. It no longer requires a large installation space and provides convenience in maintenance and repair.

What sets Seegene STARlet-AIOS apart is its unique high multiplex Real-Time PCR reagent technology. Within the same disease group such as respiratory, GI, or STI, Seegene’s syndromic test can find the exact cause of a specific symptom with a single test. Seegene’s currently available products can be applied on the STARlet-AIOS and its newly developed products will also be compatible with the solution, thus further increasing its expandability. With the all-in-one solution, diverse syndromic tests can be carried out with a single system, optimizing the testing environment.

From sample input to data analysis, Seegene STARlet-AIOS provides a streamlined process for molecular testing. The entire workflow is fully automated with Seegene’s solution. Just a click of a button is all that is needed. An inserted sample plate goes through the extraction, followed by the PCR setup process within the extraction instrument STARlet. Once the extraction and PCR setup are finished, the sample plate is moved down to the lower level by the elevator robot. The plate is then picked up by the plate handler robot and moved to the plate sealer for automated sealing process. Once the sealing is done, the plate is again picked up by the plate handler robot and put into the CFX96 for Real-Time PCR. After the PCR, Seegene’s seamless software solution provides not only accurate quantitative test results but also customized statistical analysis in an easy to see visualized format with insights.

By completely eliminating the manual process, the possibility of human error and contamination is minimized throughout the entire testing process. As a result, the medical staff can obtain accurate test results by working in a safe and efficient environment. Seegene STARlet-AIOS is a compact yet complete testing solution that generates same-day results even with small sample sizes, making it perfect for clinics and labs of all sizes.

Related Links:
Seegene, Inc. 

Gold Supplier
All-in-One Solution for All Molecular Testing
STARlet-AIOS
New
5-Part Hematology Analyzer
Cellcount-60
New
Automatic Photometer
JOLLY 103
New
Silver Supplier
3-Part Hematology Analyzer
DH26

Print article
AACC

Channels

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.